Among oncology patients receiving immune checkpoint inhibitors, the most common cardiovascular adverse events were atrial fibrillation (4.6%), myocarditis (0.5%), and pericardial effusion (0.5%).
Meta-Analysis
Cardiovascular immune-related adverse events from immune checkpoint inhibitors are rare, with atrial fibrillation, myocarditis, and pericardial effusion being the most frequently observed.
BACKGROUND: Immune checkpoint inhibitors (ICIs) are novel therapeutic agents used for various types of cancer. ICIs have revolutionized cancer treatment and improved clinical outcomes among cancer patients. However, immune-related adverse effects of ICI therapy are common. Cardiovascular immune-related adverse events (irAEs) are rare but potentially life-threatening complications. AIM: To estimate the incidence of cardiovascular irAEs among patients undergoing ICI therapy for various malignancies. METHODS: test and managed to solve it with Cochrane's leave-one-out method. The risk of bias was performed with the Cochrane's risk of bias tool. RESULTS: A total of 26 studies were included. The incidence of irAEs follows: Myocarditis: 0.5% 95% confidence interval (CI): 0.1%-0.9%; Pericardial effusion: 0.5% (95%CI: 0.1%-1.0%); Heart failure: 0.3% (95%CI: 0.0%-0.5%); Cardiomyopathy: 0.3% (95%CI: -0.1%-0.6%); atrial fibrillation: 4.6% (95%CI: 1.0%-14.1%); Myocardial infarction: 0.4% (95%CI: 0.0%-0.7%); and Cardiac arrest: 0.4% (95%CI: 0.1%-0.8%). CONCLUSION: The most common cardiovascular irAEs were atrial fibrillation, myocarditis, and pericardial effusion. Although rare, data from post market surveillance will provide estimates of the long-term prevalence and prognosis in patients with ICI-associated cardiovascular complications.
Nso et al. (Thu,) conducted a meta-analysis in Cancer. Immune checkpoint inhibitors was evaluated on Incidence of cardiovascular immune-related adverse events. Among oncology patients receiving immune checkpoint inhibitors, the most common cardiovascular adverse events were atrial fibrillation (4.6%), myocarditis (0.5%), and pericardial effusion (0.5%).